Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma

Bingul I., Vural P., Dogru-Abbasoglu S., Cil E., Uysal M.

JOURNAL OF CLINICAL LABORATORY ANALYSIS, cilt.31, sa.6, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 6
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1002/jcla.22110
  • Dergi Adı: JOURNAL OF CLINICAL LABORATORY ANALYSIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: papillary thyroid cancer, single nucleotide polymorphism, vascular endothelial growth factor, FACTOR GENE POLYMORPHISMS, BREAST-CANCER, SERUM THYROTROPIN, FACTOR VEGF, EXPRESSION, PROGNOSIS, THYROGLOBULIN, ASSOCIATION, DISEASE, LEVEL
  • İstanbul Üniversitesi Adresli: Evet

Özet

BackgroundPapillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Vascular endothelial growth factor (VEGF) is a mediator implicated with cell proliferation, differentiation and migration, and monocyte/macrophage chemotaxis. In present study, we aimed to investigate the relationship between VEGF gene polymorphisms (G+405C, T-460C, and A-2578C) and PTC susceptibility.